Weight loss from these drugs can lead to improvements in weight-related health issues like high blood pressure, pre-diabetes and high cholesterol, Dr
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
Myles likens it to adults taking a long-term prescription for, say, high blood pressure
Individuals with obesity and T2D present leptin resistance and higher circulating levels that drastically reduce the signaling of leptin in POMC neurons and the anorexigenic activity in the ARC [127,128]
